ANAVEX LIFE SCIENCES CORP.: 10-Q filed 2014-08-13

Name: ANAVEX LIFE SCIENCES CORP.: 10-Q filed 2014-08-13
Creator: ANAVEX LIFE SCIENCES CORP.

What ANAVEX LIFE SCIENCES CORP. reported in its quarterly report filed 2014-08-13 (fiscal Q3 2014): 22 published measures, 63 facts as tagged in accession 0001062993-14-004769.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-08-13
Fiscal period: fiscal Q3 2014
Accession: 0001062993-14-004769 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANAVEX LIFE SCIENCES CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-06-30	9,313,916	USD
At 2013-09-30	393,449	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-06-30	1,905,233	USD
At 2013-09-30	2,856,660	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2014-06-30	7,408,683	USD
At 2013-09-30	-2,463,211	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-1,009,090	USD	91
2013-10-02 to 2014-06-30	-1,669,313	USD	272
2013-10-01 to 2014-06-30	-1,669,313	USD	273
2013-04-01 to 2013-06-30	-151,924	USD	91
2012-10-01 to 2013-06-30	-711,541	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-10-01 to 2014-06-30	-1,742,524	USD	273
2012-10-01 to 2013-06-30	-293,065	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-10-01 to 2014-06-30	9,579,458	USD	273
2012-10-01 to 2013-06-30	283,348	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2013-10-01 to 2014-06-30	-2,327	USD	273
2012-10-01 to 2013-06-30	0	USD	273

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	39,260,098	shares	91
2013-10-01 to 2014-06-30	38,218,237	shares	273
2013-04-01 to 2013-06-30	30,240,687	shares	91
2012-10-01 to 2013-06-30	30,240,687	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	39,260,098	shares	91
2013-10-01 to 2014-06-30	38,218,237	shares	273
2013-04-01 to 2013-06-30	30,240,687	shares	91
2012-10-01 to 2013-06-30	30,240,687	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-0.03	USD/shares	91
2013-10-01 to 2014-06-30	-0.04	USD/shares	273
2013-04-01 to 2013-06-30	-0.01	USD/shares	91
2012-10-01 to 2013-06-30	-0.02	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-0.03	USD/shares	91
2013-10-01 to 2014-06-30	-0.06	USD/shares	273
2013-04-01 to 2013-06-30	-0.01	USD/shares	91
2012-10-01 to 2013-06-30	-0.02	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-06-30	1,751	USD
At 2013-09-30	0	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-10-01 to 2014-06-30	9,589	USD	273
2012-10-01 to 2013-06-30	0	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-998,833	USD	91
2013-10-01 to 2014-06-30	-2,329,608	USD	273
2013-04-01 to 2013-06-30	-125,982	USD	91
2012-10-01 to 2013-06-30	-668,960	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-06-30	8,198,600	USD
At 2013-09-30	393,449	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	8,492	USD	91
2013-10-01 to 2014-06-30	16,858	USD	273
2013-04-01 to 2013-06-30	14,855	USD	91
2012-10-01 to 2013-06-30	41,638	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-06-30	1,904,142	USD
At 2013-09-30	1,952,660	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	265,015	USD	91
2013-10-01 to 2014-06-30	388,347	USD	273
2013-04-01 to 2013-06-30	39,021	USD	91
2012-10-01 to 2013-06-30	166,584	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-06-30	38,260,098	shares
At 2013-09-30	37,237,588	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-06-30	49,604,707	USD
At 2013-09-30	38,644,523	USD

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-10,257	USD	91
2013-10-01 to 2014-06-30	660,295	USD	273
2013-04-01 to 2013-06-30	-25,942	USD	91
2012-10-01 to 2013-06-30	-42,581	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2013-10-01 to 2014-06-30	368,170	USD	273
2012-10-01 to 2013-06-30	0	USD	273

Inspect the source

Entity: ANAVEX LIFE SCIENCES CORP. / CIK 0001314052
Captured: 2026-09-20T07:51:32.244Z
SEC response SHA-256: 58235b1aa01b2e3fa186f80cce94f8ff6bd171b1d8823aeeecb0ffde54d83b04

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001314052.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))